Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2017
At a glance
- Drugs Iodine-131 tositumomab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jul 2009 New trial record